[Aplausos] Hola, buenos días. Buenos días a todos. Todos fuimos enfermos un día y lo que pensamos primeramente es, ¿cuándo vamos a salir a regresar a nuestra vida ordinaria.Lamentablemente no todos lo logramos. Y la pregunta muy básica es, ¿por qué aún existen enfermedades sin tratamiento. Tomamos este quiz, opción A.¿Por qué tratamos síntomas y no las causas de las enfermedades. Opción B, porque no todas las enfermedades reciben la misma inversión para la búsqueda de estos tratamientos. C.Porque cada cuerp ...

Summary of Niagen Bioscience Conference Call Company Overview - Niagen Bioscience is focused on the development and commercialization of nicotinamide riboside (Niagen), a molecule that elevates NAD levels in cells, which is crucial for energy metabolism and cellular repair [5][7][8] - The company has over 90 patents protecting its core molecule and has built a strong scientific foundation with extensive research [8][14] Core Points and Arguments - **Scientific Research and Clinical Studies**: Niagen has conducted 40 peer-reviewed clinical studies demonstrating the safety and efficacy of its product, particularly in age-related conditions [7][18][24] - **Unique Positioning**: Unlike many dietary supplement companies, Niagen is rooted in scientific research and intellectual property, which differentiates it from competitors that primarily engage in marketing [11][14][17] - **Regulatory Challenges**: The company faces strict regulations that prevent it from making health claims typically associated with drugs, which influences its marketing strategy [23][24] - **Market Strategy**: Niagen relies on word-of-mouth and expert endorsements rather than direct consumer claims to build trust and credibility [24][25] Recent Developments - **Product Launches**: The company launched the Niagen Plus line, which includes IV products and at-home injectables, generating significant media attention and interest from celebrities and influencers [34][35][40] - **Clinical Trials**: A phase three clinical study on Parkinson's disease with 400 participants is nearing completion, which could significantly impact the company's valuation and credibility in the biotech space [18][54] - **Financial Health**: Niagen is cash flow positive, has no debt, and does not require additional capital for its operations, which is atypical for biotech companies [52][54] Potential Risks and Concerns - **Market Competition**: The rise of fraudulent companies claiming to offer NAD products poses a risk to the overall market perception and could impact Niagen's reputation [27][29] - **Consumer Education**: There is a need to educate consumers about the differences between Niagen and other NAD products, particularly regarding bioavailability and efficacy [27][37] Future Outlook - **Injectable Products**: The company plans to introduce a self-injection product within the next year, tapping into the growing trend of self-administered health solutions [49][50] - **Pharmaceutical Opportunities**: Niagen is exploring drug indications beyond dietary supplements, which could enhance its market position and attract sophisticated investors [54] Conclusion - Niagen Bioscience is well-positioned in the NAD market with a strong scientific foundation, innovative products, and a clear strategy to navigate regulatory challenges while maintaining financial stability. The company's focus on research and quality sets it apart from competitors, and its future product developments could significantly expand its market reach and impact.

Core Insights - The article emphasizes the summer travel opportunities across Canada, highlighting Days Inn as a key accommodation provider for various summer activities and festivals [1][14]. Group 1: Regional Highlights - British Columbia offers whale watching, the Bard on the Beach Shakespeare Festival, and the Pacific National Exhibition, with Days Inns near Vancouver serving as ideal bases for these activities [2]. - Alberta features the Calgary Stampede and Country Thunder Alberta, with Days Inns in Calgary providing convenient access to these events [3]. - In Edmonton, Days Inns are centrally located for attractions like Elk Island National Park and the Edmonton Folk Music Festival [4]. - Saskatchewan hosts Country Thunder Saskatchewan, with Days Inns in Regina positioned for easy access to this country music festival [5]. - Saskatoon offers family-friendly activities, including the Saskatoon Forestry Farm Park & Zoo and Nutrien Playland, with Days Inn by Wyndham Saskatoon as a suitable accommodation option [6]. - Winnipeg's Days Inn & Suites provides access to the Royal Aviation Museum and Assiniboine Park Zoo, appealing to both aviation and nature enthusiasts [7]. - Ontario's Days Inns are well-placed for major events like Boots and Hearts and Ottawa Bluesfest, enhancing the summer entertainment experience [8][9]. - Montreal's Days Inns allow guests to enjoy the Montreal International Jazz Festival and the vibrant city atmosphere [10][11]. - In Quebec's Lanaudière region, Days Inn by Wyndham Berthierville offers proximity to natural attractions and ecological adventures [12]. - Atlantic Canada features Days Inn by Wyndham Dalhousie and Summerside, providing access to local festivals and coastal experiences [13]. Group 2: Company Overview - Days Inns - Canada operates over 105 properties with more than 8,515 rooms, covering urban, airport, and resort markets [16]. - The brand is part of Wyndham Hotels & Resorts, which is the largest hotel franchising company globally, with approximately 8,900 hotels across nearly 95 countries [16].

Financial Data and Key Metrics Changes - In Q1 2025, the company reported revenues of $30,500,000, representing a 38% year-over-year increase [8][18] - Net income for the quarter was $5,100,000, compared to a net loss of $500,000 in Q1 2024 [21] - Cash generated from operations was $7,900,000, a significant increase from $300,000 in the same period last year [22] - The company ended the quarter with $55,600,000 in cash and no debt, maintaining strong liquidity [21] Business Line Data and Key Metrics Changes - E-commerce sales grew by 31% year-over-year, contributing significantly to revenue growth [9][18] - The food grade and pharmaceutical grade Niagen ingredient business saw a 95% increase, reaching $8,000,000 [9][18] - Gross margin improved to 63.4%, up from 60.7% a year ago, driven by a favorable product mix and cost savings [18] Market Data and Key Metrics Changes - The demand for NAD-boosting products is surging, with increasing consumer awareness of Niagen as a trusted solution [12][14] - The company aims to expand its presence in clinics, targeting 1,000 clinics by the end of 2025, with a potential addressable market of 2,000 to 3,000 clinics [42] Company Strategy and Development Direction - The company is focused on reinforcing Niagen as the leading NAD-boosting solution, aligning its brand with its mission of promoting healthy aging [15][16] - The pharmaceutical application of nicotinamide riboside (NR) is a key strategic initiative, with ongoing studies and FDA dialogues [10][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustained momentum across e-commerce and ingredient businesses, raising the full-year growth outlook to 20% to 25% [22][23] - The company is committed to operational discipline and efficiency, with a focus on long-term profitability [26] Other Important Information - The company announced a new composition of matter patent granted in March, broadening its patent portfolio [11] - Management highlighted the importance of maintaining integrity and scientific rigor in the NAD supplement market [13][14] Q&A Session Summary Question: What are the emerging tailwinds for NIAGEN IV product adoption? - Management noted significant interest from clinics and physicians, with 600 clinics currently offering NIAGEN IV and expectations for increased sales [28][32] Question: Are there new promotional strategies for e-commerce? - Management indicated a focus on profitability and efficiency, with plans to increase presence on platforms like TikTok and engage with influencers [35][37] Question: What is the potential market for NIAGEN plus? - Management aims to onboard 1,000 clinics by year-end, with a larger addressable market identified [42] Question: What is the status of the injectable NIAGEN plus? - Management confirmed that an at-home version is in development, expected to be available by Q4 2025 [72][73] Question: What is the status of the FDA discussions regarding ataxia telangiectasia? - Active discussions are ongoing with the FDA, with a pre-IND submission made and feedback received [90][91]

烟酰胺腺嘌呤二核苷酸 （ NAD） 是细胞内一种关键的辅因子，广泛参与调节能量代谢、氧化损伤和炎症反应等重要生物学过程，随着年龄的增长，体内 NAD 水 平会逐渐下降，这被认为与衰老相关的诸多问题密切相关。 烟酰胺单核苷酸 （NMN） 作为 NAD 的 前体，能够有效提升体内 NAD 的 水平，近年来被作为一种抗衰老补充剂。例如 ，亿万富翁、抗衰老狂人 Bryan Johnson 在网飞 （ Netflix ） 上线的纪录片《别死：那个想长生不老的人》中透露，自己每天服用的补充剂多达 50 多片，其中就包括 NAD 的前体——NMN。 2025 年 4 月 30 日，哥本哈根大学的研究人员在 Cell 子刊 Cell Metabolism 上发表了题为： NAD depletion in skeletal muscle does not compromise muscle function or accelerate aging 的研究论文。 撰文丨王聪 编辑丨王多鱼 排版丨水成文 该研究构建了一种 诱导型骨骼肌特异性烟酰胺磷酸核糖转移酶 （ Nampt ） 基因敲除 （iSMNKO） 小鼠模型，以破坏成年小 ...

MONTRÉAL, April 3, 2025 /PRNewswire/ - BCE Inc. (TSX: BCE) (NYSE: BCE) will hold its first-quarter 2025 results conference call with the financial community on Thursday, May 8, 2025 at 8:00 am eastern. Participants will include Mirko Bibic, President and Chief Executive Officer, and Curtis Millen, Chief Financial Officer. Media are welcome to participate on a listen-only basis. To participate, please dial toll-free 1-844-933-2401 or 647-724-5455. A replay will be available until midnight on June 8, 2025 by ...

Nelson retired from the corporate world at 39 and now manages his own portfolio full-time. His focus is on under covered and unappreciated Canadian dividend stocks, excellent companies at solid values which happen to pay dividends.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation f ...

Core Insights - The presentation titled "The New Frontier of Longevity Science: Living Well Beyond Your Years" will be led by Dr. Jeffrey A. Lieberman and Dr. David A. Sinclair, focusing on advances in longevity science and the potential to extend human lifespan beyond 100 years while maintaining quality of life [2][3] Group 1: Presentation Details - The event will take place on March 10, 2025, from 2:30 p.m. to 3:30 p.m. at the JW Marriott Austin as part of SXSW 2025's Health & MedTech Track [3] - Following the presentation, Dr. Lieberman will sign copies of his book "Malady of the Mind: Schizophrenia and the Path to Prevention" at the SXSW Bookstore [4] Group 2: Speakers' Backgrounds - Dr. Jeffrey A. Lieberman is a clinical neuroscientist and psychiatrist known for his research on brain disorders and mental illness, with over 800 scientific articles published and cited more than 100,000 times [5] - Dr. David A. Sinclair is a Professor of Genetics at Harvard Medical School, recognized for his research on aging and age-related diseases, with over 180 peer-reviewed articles published and cited over 97,000 times [6][8] Group 3: Key Topics of Discussion - The presentation will cover pivotal advancements in medicine, including human genome sequencing and the discovery of Sirtuin genes, which have made altering the aging process scientifically plausible [7] - It will also discuss holistic strategies and pharmaceutical therapies aimed at enhancing health and targeting aging at the cellular level [7] - Enhanced therapeutic strategies for brain longevity will be explored, including techniques like transcranial magnetic stimulation and psychedelics [7]

ChromaDex Corporation (NASDAQ:CDXC) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Ben Shamsian - Vice President, Lytham Partners, Investor Relations Rob Fried - Chief Executive Officer Ozan Pamir - Chief Financial Officer Andrew Shao - SVP, Scientific & Regulatory Affairs Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Mitchell Pinheiro - Sturdivant Bill Dezellem - Tieton Capital Management Ram Selvaraju - H.C. Wainwright Sean McGowan - ROTH Capital J.P. Mark ...